2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. SHP2

SHP2

Src homology phosphatase 2; PTPN11

Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP). SHP2 is involved in diverse signalling pathways such as RAS-MAPK, PI3K-AKT, JAK-STAT and PD-1/PD-L1. Besides, SHP2 negatively regulates the activation of recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome via mitochondrial homeostasis. SHP2 has been regarded as an extremely attractive target for human diseases therapies, particular in cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-114397
    SHP394
    		Inhibitor 99.66%
    SHP394 is an orally active, selective and allosteric inhibitor of SHP2, with an IC50 of 23 nM.
    SHP394
  • HY-118567
    Bis(maltolato)oxovanadium(IV)
    		Inhibitor 99.89%
    Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer.
    Bis(maltolato)oxovanadium(IV)
  • HY-145703
    SHP2 protein degrader-2
    		Inhibitor 99.76%
    SHP2 protein degrader-2 (SHP2-D26) is a SHP2 protein PROTAC degrader. SHP2 protein degrader-2 reduces expression level of SHP2 in various cancer cells.
    SHP2 protein degrader-2
  • HY-131132
    JAB-3068
    		Inhibitor 99.44%
    JAB-3068 (SHP2-IN-6) is a potent SHP2 inhibitor, extracted from patent WO2017211303A1, compound 7, has an IC50 of 25.8 nM.
    JAB-3068
  • HY-131132A
    JAB-3068 hydrochloride
    		Inhibitor 98.88%
    JAB-3068 (SHP2-IN-6) hydrochloride is a potent SHP2 inhibitor with an IC50 of 25.8 nM. JAB-3068 hydrochloride is extracted from patent WO2017211303A1, compound 7.
    JAB-3068 hydrochloride
  • HY-108944
    LYP-IN-1
    		Inhibitor 99.82%
    LYP-IN-1 is a potent, selective and specific LYP inhibitor with a Ki and an IC50 of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC50=5 μM) and SHP2 (IC50=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders. LYP-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LYP-IN-1
  • HY-145159
    SHP2 protein degrader-1
    		Inhibitor 98.94%
    SHP2 protein degrader-1 is a potent allosteric inhibitor of SHP2. SHP2 protein degrader-1 induces SHP2 degradation and cell apoptosis. SHP2 protein degrader-1 has the potential for researching SHP2 related diseases.
    SHP2 protein degrader-1
  • HY-18756A
    NSC-87877 disodium
    		Inhibitor ≥98.0%
    NSC-87877 disodium is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC50 values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).
    NSC-87877 disodium
  • HY-132901
    IACS-15414
    		Inhibitor 99.39%
    IACS-15414 is a potent and orally bioavailable SHP2 inhibitor with an IC50 value of 122 nM.
    IACS-15414
  • HY-115925
    SHP2-IN-9
    		Inhibitor 98.68%
    SHP2-IN-9 is a specific SHP2 inhibitor (IC50 =1.174 μM) with enhanced blood–brain barrier penetration. SHP2-IN-9 shows 85-fold more selective for SHP2 than SHP1. SHP2-IN-9 inhibits SHP2-mediated cell signal transduction and cancer cell proliferation, and inhibits the growth of cervix cancer tumors and glioblastoma growth in vivo.
    SHP2-IN-9
  • HY-149241
    SHP2-IN-13
    		Inhibitor 99.41%
    SHP2-IN-13 is a highly selective and orally active SHP2 “tunnel site” allosteric inhibitor with an IC50 of 83.0 nM. SHP2-IN-13 has the potential for cancers bearing RTK oncogenic drivers and SHP2-related diseases research.
    SHP2-IN-13
  • HY-121879
    SHP836
    		Inhibitor 99.39%
    SHP836 is a SHP2 allosteric inhibitor, with an IC50 of 12 μM for the full length SHP2.
    SHP836
  • HY-114460
    SHP2-IN-1
    		Inhibitor ≥99.0%
    SHP2-IN-1 (compound 13) is an allergic inhibitor of SHP2 (PTPN11), with an IC50 of 3 nM.
    SHP2-IN-1
  • HY-114453
    SHP389
    		Inhibitor 98.03%
    SHP389 is an allosteric SHP2 inhibitor, with an IC50 of 36 nM for both SHP2 and p-ERK.
    SHP389
  • HY-125108
    PHPS1 sodium
    		Inhibitor 99.93%
    PHPS1 sodium is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
    PHPS1 sodium
  • HY-P3444
    CD31
    		99.33%
    CD31 (PECAM-1) is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation-.
    CD31
  • HY-152208
    BPDA2
    		Inhibitor 99.30%
    BPDA2 is a highly selective and competitive active site SHP2 inhibitor with IC50s of 92.0 nM, 33.39 μM, 40.71 μM for SHP2, SHP1, SHP1B, respectively. DBDA2 downregulates mitogenic and cell survival signaling and RTK expression. BPDA2 suppresses SHP2 mediated signaling and breast cancer cell phenotypes.
    BPDA2
  • HY-120901
    II-B08
    		Inhibitor
    II-B08 is a reversible and noncompetitive SHP2 inhibitor (IC50: 5.5 μM, 15.7, 14.3 μM for SHP2, SHP1, PTP1B). II-B08 can be used for cancer research.
    II-B08
  • HY-151464
    SHP2/HDAC-IN-1
    		Inhibitor
    SHP2/HDAC-IN-1 is a dual allosteric SHP2/HDAC inhibitor with IC50 values of 20.4 nM (SHP2) and 25.3 nM (HDAC1) respectively. SHP2/HDAC-IN-1 triggers efficient antitumor immunity by activating T cells, enhancing the antigen presentation function and promoting cytokine secretion. SHP2/HDAC-IN-1 can be used in the research of cancer immunoresearch.
    SHP2/HDAC-IN-1
  • HY-120159
    GS-493
    		Inhibitor
    GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC50 of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity.
    GS-493
Cat. No. Product Name / Synonyms Application Reactivity